Beginning in the mid-1950s, the U.S. Army conducted research involving thousands of human subjects on various chemical agents, including LSD, BZ and marijuana derivatives, to assess their utility for chemical warfare applications.
Now one of the leading participants in that enterprise, Dr. James S. Ketchum, has published a memoir entitled “Chemical Warfare: Secrets Almost Forgotten.”
“It is a detailed autobiographical reconstruction of the Edgewood Arsenal program of evaluating possible incapacitating agents in human volunteers (enlisted men) during the 1960s,” he told Secrecy News. “It reveals facts buried in restricted archives for many years and includes a voluminous appendix of research data acquired, much of which has not previously been released to the public.”
The self-published volume is a candid, not entirely flattering, sometimes morbidly amusing account of a little-documented aspect of Army research.
“I had early misgivings that my [manuscript] might raise some red flags in [the Army] Security Office, but was pleasantly surprised when none appeared,” he writes.
Among other things, Dr. Ketchum co-authored the chapter on incapacitating agents in the CBW volume of Textbook of Military Medicine.
“Definitely someone to take seriously,” a colleague of Secrecy News wrote. “Although I expect to disagree with much of his opinion, the historical information will be very useful, much of it not available elsewhere.”
Further background and book order information is available here.
Update, 6/5/19: An obituary for James Ketchum appeared in the Washington Post here.
It’s a busy time and you have things to do. Here are three things worth tracking in science policy as Fiscal Year 2026 (FY26) wraps and we head into FY27.
We’re asking the U.S. government to release holds on Congressionally-appropriated funding for scientific research, education, and critical activities at the earliest possible time.
It is in the interests of the United States to appropriately protect information that needs to be protected while maintaining our participation in new discoveries to maintain our competitive advantage.
The question is not whether the capital exists (it does!), nor whether energy solutions are available (they are!), but whether we can align energy finance quickly enough to channel the right types of capital where and when it’s needed most.